May 3 & 5 Workshop About Cancer Drug ... - SHARE Metastatic ...

SHARE Metastatic Breast Cancer

6,605 members8,140 posts

May 3 & 5 Workshop About Cancer Drug Dosing

Bestbird profile image
13 Replies

If you’re concerned about the toxicity of anticancer drugs and interested in hearing more about this important topic, you may want to attend the May 3 & 5 workshop hosted by the FDA and ASCO! Speakers and panelists will discuss research and clinical challenges regarding dose optimization, and highlight strategies to improve dose optimization for anticancer agents. I’m proud to announce that MBC patient advocates Sheila McGlown and Anne Loeser of the Patient-Centered Dosing Initiative (PCDI) will be panelists!

View more information and register for either or both days of the May 3/5 workshop at: fda.gov/news-events/fda-mee...

Written by
Bestbird profile image
Bestbird
To view profiles and participate in discussions please or .
13 Replies
Hazelgreen profile image
Hazelgreen

Thanks so much, Anne, for posting this important workshop. I will look forward to hearing the webcast afterthe event.

Bestbird profile image
Bestbird in reply to Hazelgreen

Hazelgreen, thank you for your kind words! This should indeed be an interesting opportunity to learn more about what's being done to reform the "more is better" oncology drug dosing paradigm!

NPmary profile image
NPmary

Thank you.

Nature613 profile image
Nature613

Hi Anne,Yes. Thank you for letting us know about this. This is good stuff.

Best wishes.

LadyKatarina profile image
LadyKatarina

Do you know if they are doing any new studies using lower doses of the AI's and /or fulvestrant? I have some papers but they are older. And thank you so much for all of your hard work on this topic! I can't believe you have the energy to do what you have done--so thankful. Kay

Bestbird profile image
Bestbird in reply to LadyKatarina

LadyKatarina, I'm not aware of any new studies regarding already-approved endocrine therapies, but that doesn't mean that someone somewhere isn't addressing the issue. That said, I doubt there'll be a future study about Fulvestrant dose de-escalation because it was initially approved at 250 mg and it was subsequently found that it was more effective at 500 mg, which became the new approved dose.

OneLump22 profile image
OneLump22 in reply to Bestbird

*loud whistle* 500mg? Wow. Not sure if that's good or bad. Just sounds like a lot. To me anyway, but I'm not a medical professional. That could be nothing for all I know.

TammyCross profile image
TammyCross in reply to OneLump22

As I understand it, that was all they could inject, and that is why they have to use both hips. The oral SERDs, one oncologist told me, are more effective because they can increase how much is delivered.

Bestbird profile image
Bestbird in reply to TammyCross

It has to do with bioavailability.

LadyKatarina profile image
LadyKatarina

Thank you so much! Best to you--Kay

OneLump22 profile image
OneLump22

Yes! So will I. I have been very concerned about some of my meds.

TammyCross profile image
TammyCross

This looks fascinating and important -- finding new ways to discover optimal dose, not just highest tolerated dose. (I say this as I face starting on highest dose of Verzenio, and going down only if the side effects are too much for me. Seems like a dumb way to go. Why not start on the lowest dose, and work up?)

I cannot attend. Will recordings be available -- or materials that can be downloaded after the conference? I am sure people here will share important nuggets. What I really wish is that we could make our docs attend.

Bestbird profile image
Bestbird in reply to TammyCross

Yes, recordings will be available in a few weeks.

You may also like...

A HUGE Change Regarding Dosing!

Shortly after the Patient-Centered Dosing Initiative's presentation about MBC patients’...

\"Your cancer may be changing course.\"

mean? For the first time since I was diagnosed w/MBC 3 1/2 years ago, I have had recent progression...

Someone was talking about skin cancer

ErSO drug that might cure a metastatic breast cancer is undergoing preclinical testing

email I received from the Director of research center in NCI(National Cancer Institute) The ErSO...

Genomic testing for the right drug for your type of cancer cell.